Page 1454 - Williams Hematology ( PDFDrive )

1428 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1429

847. Minderman H, Zhou Y, O’Loughlin KL, Baer MR: Bortezomib activity and in vitro 876. Seiter K, Feldman EJ, Dorota Halicka H, et al: Clinical and laboratory evaluation of
interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are all-trans retinoic acid modulation of chemotherapy in patients with acute myeloge-
independent of multidrug resistance mechanisms and p53 status. Cancer Chemother nous leukaemia. Br J Haematol 108:40, 2000.
Pharmacol 60:245, 2007. 877. Chen Z, Wang Y, Wang W, et al: All-trans retinoic acid as a single agent induces com-
848. Frelin C, Imbert V, Griessinger E, et al: Targeting NF-kappaB activation via pharma- plete remission in a patient with acute leukemia of M2a subtype. Chin Med J 115:58,
cologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. 2002.
Blood 105: 804, 2005. 878. Lehman S, Bengtzen S, Paul A, et al: Effects of arsenic trioxide (As O ) on leukemic
3
2
849. Stone RM: Novel therapeutic agents in acute myeloid leukemia. Exp Hematol 35(Suppl cells from patients with non-M3 acute myelogenous leukemia: Studies of cytotoxicity,
1):163, 2007. apoptosis and the pattern of resistance. Eur J Haematol 66:357, 2001.
850. Chalandon Y, Schwaller J: Targeting mutated protein tyrosine kinases and their sig- 879. Ozturk A, Orhan B, Turken O, et al: Acute myeloblastic leukemia achieving complete
naling pathways in hematologic malignancies. Haematologica 90:949, 2005. remission with amifostine alone. Leuk Lymphoma 43:451, 2002.
851. Tamburini J, Chapuis N, Bardet V, et al: Mammalian target of rapamycin (mTOR) 880. Steins MB, Padro T, Bieker R, et al: Efficacy and safety of thalidomide in patients with
inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like acute myeloid leukemia. Blood 99:834, 2002.
growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeu- 881. Cabebe E, Wakelee H: Sunitinib: A newly approved small-molecule inhibitor of angio-
tic inhibition of both pathways. Blood 111:379, 2008. genesis. Drugs Today (Barc) 42:387, 2006.
852. Wei G, Twomey D, Lamb J, et al: Gene expression-based chemical genomics identifies 882. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø: Antiangiogenic therapy in acute
rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10:331, myelogenous leukemia: Targeting of vascular endothelial growth factor and interleu-
2006. kin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 5:229, 2005.
853. Kojima K, Shimanuki M, Shikami M, et al: The dual PI3 kinase/mTOR inhibitor 883. Kitagawa M: The angiopoietin signaling pathway as a promising target for the treat-
PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mito- ment of acute myeloid leukemia. Haematologica 91:1155B, 2006.
chondrial apoptosis in p53 wild-type AML. Leukemia 22:1728, 2008. 884. Lancet JE, List AF, Moscinski LC, et al: Treatment of deletion 5q acute myeloid leuke-
854. Martelli AM, Nyåkern M, Tabellini G, et al: Phosphoinositide 3-kinase/Akt signaling mia with lenalidomide. Leukemia 21:586, 2007.
pathway and its therapeutical implications for human acute myeloid leukemia. Leuke- 885. Burger JA, Bürkle A: The CXCR4 chemokine receptor in acute and chronic leukaemia:
mia 20:911, 2006. A marrow homing receptor and potential therapeutic target. Br J Haematol 137:288,
855. Papa V, Tazzari PL, Chiarini F, et al: Proapoptotic activity and chemosensitizing effect 2007.
of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 886. Zeng Z, Samudio IJ, Munsell M, et al: Inhibition of CXCR4 with the novel RCP168
22:147, 2008. peptide overcomes stroma-mediated chemoresistance in chronic and acute leuke-
856. Milella M, Kornblau SM, Estrov Z, et al: Therapeutic targeting of the MEK/MAPK mias. Mol Cancer Ther 5:3113, 2006.
signal transduction module in acute myeloid leukemia. J Clin Invest 108:851, 2001. 887. Andreeff M, Konopleva M: Mechanisms of drug resistance in AML. Cancer Treat Res
857. Ikezoe T, Yang J, Nishioka C, et al: A novel treatment strategy targeting Aurora kinases 112:237, 2002.
in acute Myelogenous leukemia. Mol Cancer Ther 6:1851, 2007. 888. Van der Kolk DM, De Vries EG, Muller M, Vellenga E: The role of drug efflux pumps
858. Thomas X, Campos L, Le QH, Guyotat D: Heat shock proteins and acute leukemias. in acute myeloid leukemia. Leuk Lymphoma 43:685, 2002.
Hematology 10:225, 2005. 889. Claxton D, Choudhury A: Potential for therapy with AML-derived dendritic cells.
859. Hu S, Niu H, Minkin P, et al: Comparison of antitumor effects of multitargeted Leukemia 15:668, 2001.
tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 7:1110, 890. Rosenblatt J, Avigan D: Can leukemia-derived dendritic cells generate antileukemia
2008. immunity? Expert Rev Vaccines 5:467, 2006.
860. Raanani P, Shpilberg O, Ben-Bassat I, et al: Extramedullary disease and targeted ther- 891. Panoskaltsis N: Dendritic cells in MDS and AML—Cause, effect or solution to the
apies for hematological malignancies—Is the association real? Ann Oncol 18:7, 2007. immune pathogenesis of disease? Leukemia 19:354, 2005.
861. Shangary S, Johnson DE: Recent advances in the development of anticancer agents 892. Woiciechowsky A, Regn S, Kolb H-J, Roskrow M: Leukemic dendritic cells generated
targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 17:1470, 2003. in the presence of FLT3 ligand have the capacity to stimulate an autologous leuke-
862. Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and mia-specific cytotoxic T cell response from patients with acute myeloid leukemia.
resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell Leukemia 15:246, 2001.
10:375, 2006. 893. Stripecke R, Levine AM, Pullarkat V, Cardoso AA: Immunotherapy with acute leu-
863. Konopleva M, Watt J, Contractor R, et al: Mechanisms of antileukemic activity of the kemia cells modified into antigen-presenting cells: Ex vivo culture and gene transfer
novel Bcl-2 homology domain-3 mimetic GX15–070 (obatoclax). Cancer Res 68:3413, methods. Leukemia 16:1974, 2002.
2008. 894. Galea-Lauri J, Darling D, Mufti G, et al: Eliciting cytotoxic T lymphocytes against
864. Konopleva M, Tsao T, Ruvolo P, et al: Novel triterpenoid CDDO-Me is a potent acute myeloid leukemia-derived antigens: Evaluation of dendritic cell-leukemia cell
inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99:326, hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
2002. Cancer Immunol Immunother 51:299, 2002.
865. Morgan MA, Ganser A, Reuter CWM: Therapeutic efficacy of prenylation inhibitors 895. Cooper MA, Caligiuri MA: Immunologic manipulation in AML: From bench to bed-
in the treatment of myeloid leukemia. Leukemia 17:1482, 2003. side. Leukemia 16:736, 2002.
866. Kurzrock R, Cortes J, Kantarjian H: Clinical development of farnesyltransfer- 896. Meloni G, Trisolini SM, Capria S, et al: How long can we give interleukin-2? Clinical
ase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol 39:20, and immunological evaluation of AML patients after 10 or more years of IL2 admin-
2002. istration. Leukemia 16:2016, 2002.
867. Brunner TB, Hahn SM, Gupta AK, et al: Farnesyltransferase inhibitors: An overview 897. Baer MR, George SL, Caligiuri MA, et al: Low-dose interleukin-2 immunotherapy
of the results of preclinical and clinical investigations. Cancer Res 63:5656, 2003. does not improve outcome of patients age 60 years and older with acute myeloid leu-
868. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of the farnesyl- kemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin
transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: Oncol 26:4934, 2008.
A phase 1 clinical-laboratory correlative trial. Blood 97:3361, 2001. 898. Elisseeva OA, Oka Y, Tsuboi A, et al: Humoral immune responses against Wilms
869. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ: Lovastatin induced control of tumor gene WT1 product in patients with hematopoietic malignancies. Blood
blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lym- 99:3272, 2002.
phoma 40:659, 2001. 899. Molldrem J: Immune therapy of AML. Cytotherapy 4:437, 2002.
870. Lishner M, Bar-Sef A, Elis A, Fabian I: Effect of simvastatin alone and in combination 900. Norde WJ, Hobo W, van der Voort R, et al: Coinhibitory molecules in hematologic
with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig malignancies: Targets for therapeutic intervention. Blood 120:728, 2012.
Med 49:319, 2001. 901. Choo A, Palladinetti P, Holmes T, et al: SiRNA targeting the IRF2 transcription factor
871. Li HY, Appelbaum FR, Willman CL, et al: Cholesterol-modulating agents kill acute inhibits leukaemic cell growth. Int J Oncol 33:175, 2008.
myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cho- 902. Klisovic RB, Blum W, Wei X, et al: Phase I study of GTI-2040, an antisense to ribonu-
lesterol responses. Blood 101:3628, 2003. cleotide reductase, in combination with high-dose cytarabine in patients with acute
872. Munker R, Kobayashi T, Eistner E, et al: A new series of vitamin D analogs is highly myeloid leukemia. Clin Cancer Res 14:3889, 2008.
active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leuke- 903. Stevenson GT: CD38 as a therapeutic target. Mol Med 12:345, 2006.
mia. Blood 88:2201, 1996. 904. Abutalib SA, Tallman MS: Monoclonal antibodies for the treatment of acute myeloid
873. Morosetti R, Grignani F, Liberatore C, et al: Infrequent alterations of the RAR alpha leukemia. Curr Pharm Biotechnol 7:343, 2006.
gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leu- 905. Wayne AS, FitzGerald DJ, Kreitman RJ, et al: Immunotoxins for leukemia. Blood
kemias, myelodysplastic syndromes, and cell lines. Blood 87:4399, 1996. 123:2470, 2014.
874. Usuki K, Kitazume K, Endo M, et al: Combination therapy with granulocyte colony- 906. Curti A, Ruggeri L, D’Addio A, et al: Successful transfer of alloreactive haploidenti-
stimulating factor, all-trans retinoic acid, and low-dose cytotoxic drugs for acute mye- cal KIR ligand-mismatched natural killer cells after infusion in elderly after high risk
logenous leukemia. Intern Med 34:1186, 1995. acute myeloid leukemia patients. Blood 11:3273, 2011.
875. Zhang W, Piatyszek MA, Kobayashi T, et al: Telomerase activity in human acute 907. Sekeres MA, Gundacker H, Lancet J, et al: A phase 2 study of lenalidomide monother-
myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing apy in patients with 5q acute myeloid leukemia: Southwest Oncology Group Study
agents. Clin Cancer Res 2:799, 1996. S0605. Blood 118: 523, 2011.

Kaushansky_chapter 88_p1373-1436.indd 1429 9/21/15 11:02 AM